The Role of Self-congruity in Consumer Preferences: Perspectives from Transaction Records

Personalised marketing is more persuasive than traditional techniques aimed at the masses, however marketers do not always have access to consumers’ private attributes in order to apply these insights. The effect of personalisation is based on an established theory in consumer psychology – self-congruity theory – which posits that individuals prefer products, brands and advertisements that embody characteristics that match with their self-concepts. Self-congruence not only enhances marketing effectiveness, it can also be used to improve consumer well-being. While it has been established that consumers who spend in a way that is more congruent with their personality are happier, clarifications around the types of individuals who are more or less likely to engage in self-congruent spending, as well as the moderating effects on the benefit in happiness from such consumption could inform policy for improving happiness at a collective level. This thesis contributes to a growing body of research which attempts to understand how consumption patterns are related to consumers’ characteristics, its applications in advertising, as well as consumer well-being. By using a dataset containing more than 1 million transactions recorded over a period of 12-months, the thesis demonstrates the value of the digital footprint in the form of bank transactions for enriching our understanding of key questions in consumer research, underpinned by the theory of self-congruity. This thesis combines methods from computational social science with personality psychology to test research questions on consumer preferences. Two components of the thesis focused on the predictive utility of transaction records in inferring consumer attributes with which to personalise advertising, as well as the use of transaction records in examining self-congruence in overall consumption patterns and its relationship with happiness. Through five empirical studies, this work suggests that consumer attributes such as age and financial distress can be reliably inferred from consumption patterns reflected in transaction records (Chapter 3 and 5). The inferred age can be used to personalise advertisements in order to increase their appeal (Chapter 4). Using an objective measure of self-congruence in overall consumption pattern computed from transaction records and panel ratings, the thesis shows that individuals differ in their tendency to spend in a way that is congruent with their personality based on their levels of materialism and financial distress (Chapter 6). As the most important predictor of self-congruent spending, financial distress moderates the relationship between self-congruent spending and happiness (Chapter 7). These findings contribute insights into how consumption patterns are related to consumer attributes and usefulness for personalisation in marketing, as well as policy recommendations for improving well-being by targeting consumption patterns in financially distressed individuals. In addition, this thesis also showcases the value of machine learning and large-scale behavioural field data in the study of consumer psychology. Privacy and ethical concerns surrounding automated profiling and microtargeting are also cautioned

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Short-term fouling propensity and flux behavior in an osmotic membrane bioreactor for wastewater treatment

10.1016/j.desal.2013.11.010Desalination33291-99DSLN

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo